Search results for: 'Cancer Diagnostics Market'

26 Aug 2024  |  Global  |  Market Research

Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024 2029

Companion Diagnostics-specific Advanced Staining and Multiomics Capabilities are Driving Market Growth

Infographics

×

The global tissue diagnostics market will experience significant growth driven by the need for advanced staining in precise biomarker identification in personalized medicine, tissue biopsy test volumes, and pre-analytical and advanced staining platform development. According to the WHO, there will be a 60% rise in cancer cases worldwide by 2040,...

This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast by segment, drivers and restraints, and technology trends, along with the competitive factors and strategies, and key companies to watch. The global market is primarily driven by the high prevalen...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

20 Jan 2025  |  Global  |  Market Research

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

Infographics

×

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highligh...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry. The COVID-19 pandemic left a lot of installed capacity in laboratories and healthcare centers. To take advantage of this situation, it is necessary for industry players to focus on ...

23 May 2017  |  North America  |  Market Research

Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021

US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation

Infographics

×

The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of c...

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...